These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3792614)

  • 1. Nontransferrin-bound serum iron in thalassemia and sickle cell patients.
    Ahmed NK; Hanna M; Wang W
    Int J Biochem; 1986; 18(10):953-6. PubMed ID: 3792614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
    Breuer W; Ronson A; Slotki IN; Abramov A; Hershko C; Cabantchik ZI
    Blood; 2000 May; 95(9):2975-82. PubMed ID: 10779448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias.
    Wang WC; Ahmed N; Hanna M
    J Pediatr; 1986 Apr; 108(4):552-7. PubMed ID: 3083076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
    Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
    J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
    Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nontransferrin-bound iron in transfused patients with sickle cell disease.
    Inati A; Musallam KM; Cappellini MD; Duca L; Taher AT
    Int J Lab Hematol; 2011 Apr; 33(2):133-7. PubMed ID: 21382180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.
    Porter JB; Walter PB; Neumayr LD; Evans P; Bansal S; Garbowski M; Weyhmiller MG; Harmatz PR; Wood JC; Miller JL; Byrnes C; Weiss G; Seifert M; Grosse R; Grabowski D; Schmidt A; Fischer R; Nielsen P; Niemeyer C; Vichinsky E
    Br J Haematol; 2014 Dec; 167(5):692-6. PubMed ID: 25209728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High nontransferrin bound iron levels and heart disease in thalassemia major.
    Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD
    Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity.
    Hershko C; Graham G; Bates GW; Rachmilewitz EA
    Br J Haematol; 1978 Oct; 40(2):255-63. PubMed ID: 708645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
    Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
    Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
    Pippard MJ
    Acta Haematol; 1987; 78(2-3):206-11. PubMed ID: 3120473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment of Cooley's anemia. Intravenous chelation therapy.
    Cohen AR; Martin M; Schwartz E
    Ann N Y Acad Sci; 1990; 612():286-92. PubMed ID: 2291556
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
    Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
    Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive method for nontransferrin-bound iron quantification by graphite furnace atomic absorption spectrometry.
    Jakeman A; Thompson T; McHattie J; Lehotay DC
    Clin Biochem; 2001 Feb; 34(1):43-7. PubMed ID: 11239514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to long-term deferoxamine therapy in thalassemia.
    Cohen A; Martin M; Schwartz E
    J Pediatr; 1981 Nov; 99(5):689-94. PubMed ID: 7299539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-transferrin-bound iron in platelet concentrates promotes the growth of Staphylococcus epidermidis.
    Matinaho S; Parkkinen J
    Transfusion; 2005 Jun; 45(6):927-33. PubMed ID: 15934991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.